Payment overview · 2025
General Payments
$1,629.50
76 reported records · 24 companies
Healthcare provider profile · identity verified
Christopher Michael Porter, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LANCASTER, PA · NPI 1598831760
Verified facts
What the public records show
CMS Open Payments records show Christopher Michael Porter, D.O. received $1,629.50 in general payments during 2025 across 76 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 890 claims for Eliquis by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.59 | 12.4% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.50 | 9.2% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $125.76 | 7.7% | 6 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $117.15 | 7.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $106.57 | 6.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $102.47 | 6.3% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $92.76 | 5.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $85.85 | 5.3% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$77.16 | 4.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.10 | 4.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $71.13 | 4.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $70.59 | 4.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.39 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.34 | 3.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.12 | 2.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $33.70 | 2.1% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.02 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.05 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.37 | 1.4% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $20.60 | 1.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.43 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.74 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.51 | 1.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.60 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,537.85 | 73 |
| Education | $91.65 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $188.32 | 10 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $125.76 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.81 | 5 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $117.15 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $115.07 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $106.57 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $92.76 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.30 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80.30 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $71.13 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $70.59 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.71 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $63.03 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $62.55 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.39 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.99 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.99 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.37 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.44 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 121 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 162 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
107 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
121 | 119 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
251 | 29 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
890 | 81 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1135 | 179 |
| Eliquis | Apixaban | 890 | 81 |
| Sertraline Hcl | Sertraline Hcl | 747 | 93 |
| Gabapentin | Gabapentin | 742 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 707 | 122 |
| Furosemide | Furosemide | 610 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 519 | 86 |
| Potassium Chloride | Potassium Chloride | 413 | 68 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 406 | 36 |
| Lisinopril | Lisinopril | 390 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 380 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 378 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 348 | 56 |
| Mirtazapine | Mirtazapine | 333 | 48 |
| Xarelto | Rivaroxaban | 301 | 22 |
| Trazodone Hcl | Trazodone Hcl | 295 | 40 |
| Donepezil Hcl | Donepezil Hcl | 289 | 42 |
| Simvastatin | Simvastatin | 280 | 51 |
| Trulicity | Dulaglutide | 251 | 29 |
| Metformin Hcl | Metformin Hcl | 244 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 234 | 33 |
| Carvedilol | Carvedilol | 218 | 38 |
| Buspirone Hcl | Buspirone Hcl | 211 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 209 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 202 | 34 |
| Divalproex Sodium | Divalproex Sodium | 200 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 47 |
| Losartan Potassium | Losartan Potassium | 182 | 35 |
| Warfarin Sodium | Warfarin Sodium | 180 | 17 |
| Risperidone | Risperidone | 176 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 175 | 18 |
| Omeprazole | Omeprazole | 170 | 41 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 168 | 25 |
| Famotidine | Famotidine | 165 | 29 |
| Jardiance | Empagliflozin | 162 | 21 |
| Levetiracetam | Levetiracetam | 160 | 18 |
| Torsemide | Torsemide | 160 | 21 |
| Olanzapine | Olanzapine | 153 | 20 |
| Baclofen | Baclofen | 152 | 25 |
| Bumetanide | Bumetanide | 152 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 144 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 137 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 135 | 16 |
| Memantine Hcl | Memantine Hcl | 133 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 20 |
| Lorazepam | Lorazepam | 126 | 34 |
| Humalog Kwikpen U-100 | Insulin Lispro | 124 | 19 |
| Sucralfate | Sucralfate | 122 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 121 | 119 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 115 | 69 |
| Finasteride | Finasteride | 113 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 62 |
| Doxycycline Hyclate | Doxycycline Hyclate | 111 | 54 |
| Myrbetriq | Mirabegron | 107 | suppressed |
| Latanoprost | Latanoprost | 104 | 30 |
| Prednisone | Prednisone | 103 | 53 |
| Ropinirole Hcl | Ropinirole Hcl | 102 | 17 |
| Alendronate Sodium | Alendronate Sodium | 98 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | suppressed |
| Spironolactone | Spironolactone | 97 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 89 | 38 |
| Ezetimibe | Ezetimibe | 86 | 16 |
| Lamotrigine | Lamotrigine | 86 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 81 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 36 |
| Nyamyc | Nystatin | 77 | 34 |
| Cephalexin | Cephalexin | 76 | 39 |
| Levemir Flexpen | Insulin Detemir | 76 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 74 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 18 |
| Ceftriaxone | Ceftriaxone Sodium | 73 | 29 |
| Januvia | Sitagliptin Phosphate | 72 | 13 |
| Midodrine Hcl | Midodrine Hcl | 70 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 66 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 66 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 14 |
| Atenolol | Atenolol | 63 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 11 |
| Bupropion Xl | Bupropion Hcl | 60 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | suppressed |
| Levemir | Insulin Detemir | 60 | suppressed |
| Ozempic | Semaglutide | 60 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 58 | 11 |
| Meloxicam | Meloxicam | 58 | 12 |
| Primidone | Primidone | 57 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 56 | 14 |
| Travoprost | Travoprost | 56 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 17 |
| Lidocaine Hcl | Lidocaine Hcl | 50 | 31 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 50 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 49 | 13 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 29 |
| Digoxin | Digoxin | 43 | suppressed |
| Allopurinol | Allopurinol | 42 | 15 |
| Aripiprazole | Aripiprazole | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 21 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 41 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 15 |
| Ketoconazole | Ketoconazole | 39 | 15 |
| Lithium Carbonate | Lithium Carbonate | 39 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 24 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 31 |
| Anastrozole | Anastrozole | 37 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 37 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 36 | 17 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 35 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Metolazone | Metolazone | 33 | suppressed |
| Rivastigmine | Rivastigmine | 33 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 33 | 18 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 21 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 31 | suppressed |
| Calcium Acetate | Calcium Acetate | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 13 |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 28 | suppressed |
| Enulose | Lactulose | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Xcopri | Cenobamate | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 15 |
| Linzess | Linaclotide | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Zonisamide | Zonisamide | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 13 |
| Dutasteride | Dutasteride | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 24 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 23 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 13 |
| Ondansetron Odt | Ondansetron | 23 | 14 |
| Paliperidone Er | Paliperidone | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Clozapine | Clozapine | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | 14 |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 17 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 19 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 19 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Perphenazine | Perphenazine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 16 |
| Budesonide | Budesonide | 18 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Mesalamine | Mesalamine | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Tresiba | Insulin Degludec | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Nystatin | Nystatin | 17 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 16 | 14 |
| Morphine Sulfate | Morphine Sulfate | 16 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Sunitinib Malate | Sunitinib Malate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,629.50 · 76 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, BRIXADI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FARXIGA, IBSRELA, INGREZZA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, ONPATTRO, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error